An interventional study of Temporal Interference Stimulation and Temporal Interference Stimulation in Parkinson Disease (PD), sponsored by Ke Dong, MD. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Ke Dong, MD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.
Among the 279 studies in Parkinson Disease with a site in China, this one is the 110th largest by planned enrollment of the 211 interventional ones that give a count, is one of 41 that started in 2026, is one of 115 with no phase, reaches primary completion later than 62 of the 134 other live ones, and was the 267th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Anhui Medical University · Sites in China
Ages 30–75
Hoffmann-La Roche · Sites in China, United States, Ireland and 2 more countries
Ages 40–85
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 18–80
Shanghai UniXell Biotechnology Co., Ltd · Sites in China
Ages 30–75
Ruijin Hospital · Sites in China
Ages 50–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 28 · Phase 3 23 · Phase 4 11
First in 2003; this study’s year is marked. 41 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 47 across the 211 interventional studies, 215 across the 68 observational. Of the 97 that completed or were terminated, 19 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 279 have an industry lead sponsor. The 10 most frequent:
Ke Dong, MD is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Ke Dong, MD has 3 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
41 of the studies in Parkinson Disease with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725562Phase 3Zhejiang Vimgreen Pharmaceuticals, Ltd.VG081821AC Tablets for Early to Mid-stage Parkinson's Disease | 2027-10-01 |
| NCT07028632iRegene Therapeutics Co., Ltd.The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | 2026-12 |
| NCT07604116Synusight Biotech (Shanghai) Co., Ltd.A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA | 2026-12 |
| NCT06642454Anhui Medical UniversityA Randomized Double-Blind Active-Controlled Crossover Trial of Respiratory-Gated Versus Non-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease | 2026-12-01 |
| NCT07384429YangPanEffects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease | 2026-12-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 279 studies in Parkinson Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial will evaluate the efficacy of accelerated Temporal Interference Stimulation (TIS) as a therapeutic intervention for individuals diagnosed with Parkinson's disease. Different frequency TIS will be delivered targeting the bilateral subthalamic nuclei of the brain according to the patient's clinical symptoms. Specifically, the basal thalamic nuclei on the side opposite to the side where the patient's symptoms are most severe receive stimulation at 130 Hz, whilst those on the other side receive stimulation at 60 Hz. The primary objective is to assess whether accelerated TIS yields measurable improvements in motor performance and verbal speech function among enrolled subjects. Functional magnetic resonance imaging (fMRI) will be adopted as an auxiliary imaging modality to objectively characterize underlying cerebral functional alterations induced by accelerated TIS intervention. The core scientific research questions to be addressed in this trial are listed as follows:
Will different frequency accelerated TIS administered to the bilateral subthalamic nuclei produce significant improvements in motor function and cognitive function among enrolled subjects with Parkinson-related disorders? What quantitative and qualitative modifications in cerebral functional activity will be detected via fMRI after standardized accelerated TIS intervention administration? Investigators will implement a two-arm parallel controlled comparative design for all enrolled eligible subjects. This design remains a parallel design, with two independent groups of subjects receiving different active interventions simultaneously rather than a sham control. All confirmed Parkinson's disease patients will undergo standardized random grouping and be allocated into two independent research arms. Subjects in the experimental arm will receive continuous, standardized TIS intervention targeting bilateral subthalamic nuclei, with the basal thalamic nuclei on the side opposite to the side where the patient's symptoms are most severe receiving stimulation at 130 Hz, and those on the other side receiving stimulation at 60 Hz. Subjects in the control arm will receive continuous, standardized TIS intervention targeting bilateral subthalamic nuclei with bilateral 130 Hz stimulation. The control intervention adopts identical operation procedures, equipment wearing mode and on-site operating environment as the formal TIS intervention, with the only difference being the stimulation frequency setting (bilateral 130 Hz in the control arm versus asymmetric frequency in the experimental arm). Rigorous controlled grouping design will ensure objective, verifiable data support for verifying the actual intervention efficacy of different frequency TIS modes on motor dysfunction and speech impairment in Parkinson-related patients, and will also help to clarify the potential advantages of asymmetric frequency TIS over bilateral same-frequency TIS.
All enrolled subjects will complete the following standardized trial procedures in full compliance with the trial protocol:
Receive continuous targeted intervention of either formal asymmetric frequency TIS (130 Hz on the contralateral side of severe symptoms, 60 Hz on the ipsilateral side) or bilateral 130 Hz TIS control intervention on bilateral subthalamic nuclei, with consecutive 5-day fixed-course administration in strict accordance with trial operating specifications.
Complete unified fMRI brain scanning examinations and standardized motor function as well as speech function quantitative evaluation assessments at two fixed time nodes, including the baseline time point before intervention initiation and the follow-up time point after all intervention courses are completed.
Truthfully record all adverse reactions and abnormal physical discomfort symptoms that occur throughout the whole intervention and follow-up observation cycle in standardized adverse event registration forms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with Parkinson's disease in the active stimulation group will receive sequential bilateral subthalamic nucleus (STN) temporal interference electrical stimulation therapy twice daily, with each session lasting 40 minutes and a rest interval of at least 1 hour between treatments. The stimulation target is the bilateral subthalamic nucleus, with individualized electrode placement and current intensity determined via personalized modeling based on each patient's magnetic resonance imaging (MRI) data. For the stimulation protocol, a unified carrier frequency of 2000 Hz is adopted for bilateral STN intervention. Specifically, TI stimulation with an envelope frequency of 130 Hz is delivered to the STN contralateral to the patient's most symptomatic side, while TI stimulation with an envelope frequency of 60 Hz is administered to the STN ipsilateral to the patient's most symptomatic side.
Device: Temporal Interference Stimulation
Participants diagnosed with Parkinson's disease in the active control group will receive sequential bilateral subthalamic nucleus (STN) temporal interference electrical stimulation therapy twice daily, with each session lasting 40 minutes and a rest interval of at least 1 hour between treatments. The stimulation target is the bilateral subthalamic nucleus, with individualized electrode placement and current intensity determined via personalized modeling based on each patient's magnetic resonance imaging (MRI) data. The active stimulation uses two distinct high frequencies (2000 Hz and 2130 Hz) to generate a therapeutic interference field.
Device: Temporal Interference Stimulation
Sequential bilateral subthalamic nucleus (STN) temporal interference electrical stimulation, administered twice daily (40 minutes per session, ≥1 hour rest interval between sessions). Stimulation targets are bilateral STN, with individualized electrode placement and current intensity determined via personalized modeling from patient MRI data. A fixed carrier frequency of 2000 Hz is used for all STN stimulation. Specifically, therapeutic temporal interference stimulation with an envelope frequency of 130 Hz is delivered to the STN contralateral to the patient's most symptomatic side, while stimulation with an envelope frequency of 60 Hz is applied to the STN ipsilateral to the most symptomatic side to produce targeted therapeutic interference fields.
Also known as: TIS, TI Stimulation, TI, tTIS, Transcranial Temporal Interference Stimulation
Sequential bilateral subthalamic nucleus (STN) temporal interference electrical stimulation (active control), administered twice daily (40 minutes per session, ≥1 hour rest interval between sessions). Stimulation targets are bilateral STN, with individualized electrode placement and current intensity determined via personalized modeling from patient MRI data. The active control stimulation uses two distinct high frequencies (2000 Hz and 2130 Hz) to generate a therapeutic interference field.
Also known as: TIS, TI, TI Stimulation, Transcranial Temporal Interference Electrical Stimulation, tTIS
The score of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III)
The MDS-UPDRS-III is a standardized assessment tool to evaluate motor function symptoms in people with Parkinson's disease.It has a scoring range of 0 to 132 points, with higher scores meaning more severe motor disorders.
Time frame: From enrollment to 1 month after treatment
The scores of Mini-BESTest
The Mini-BESTest is a clinical assessment tool for evaluating balance function. It assesses the balance control system across multiple domains, with a scoring range of 0 to 28 points; higher scores indicate better balance function.
Time frame: From enrollment to 1 month after treatment
10-Meter Walk Test
The 10-Meter Walk Test assesses gait speed and functional mobility by measuring the time required to walk 10 meters. Increased time reflects slower walking and worse mobility.
Time frame: From the enrollment to 1 month after treatment
Voice intensity
Voice intensity is measured using Praat software. Voice intensity, expressed in dB SPL, reflects the loudness of the voice. This indicators is used to objectively evaluate the functional status of the subjects' vocal system. Abnormalities in voice intensity may indicate impairments in vocal cord movement, laryngeal muscle control, or related neural regulation, which is of great significance for assessing the severity of vocal function disorders and the effect of intervention.
Time frame: From the enrollment to 1 month after treatment
Velocity of center of pressure (COP) sway
Center of pressure (COP) sway velocity of subjects on stable and unstable surfaces is measured via a balance board during two standing conditions: single-task quiet standing and dual-task standing. The dual-task standing requires subjects to continuously perform serial subtraction of 7 from random numbers ranging from 400 to 600 while maintaining standing posture. The balance board records COP movement speed under both single-task and dual-task standing states. This indicator objectively assesses balance control and adaptability to different surfaces; abnormal increases indicate impaired balance, aiding evaluation of balance disorder severity and intervention effectiveness.
Time frame: From the enrollment to 1 month after treatment
BOLD-fMRI
Functional MRI is used to acquire BOLD data. BOLD signals reflect regional brain activity and functional connectivity. This measure evaluates brain function and structural connectivity associated with motor and cognitive performance.
Time frame: From the enrollment to 1 month after treatment
Phonation duration
Phonation duration refers to the continuous time of voluntary phonation. This indicators is used to objectively evaluate the functional status of the subjects' vocal system. Abnormalities in phonation duration may indicate impairments in vocal cord movement, laryngeal muscle control, or related neural regulation, which is of great significance for assessing the severity of vocal function disorders and the effect of intervention.
Time frame: From the enrollment to 1 month after treatment
Fundamental frequency (F₀)
Fundamental frequency (F₀) range of subjects' phonation is measured using Praat software. Fundamental frequency range is the interval between the minimum and maximum F₀ (unit: Hz) during phonation, reflecting the variability of voice pitch. This indicators is used to objectively evaluate the functional status of the subjects' vocal system. Abnormalities in F₀ range may indicate impairments in vocal cord movement, laryngeal muscle control, or related neural regulation, which is of great significance for assessing the severity of vocal function disorders and the effect of intervention.
Time frame: From the enrollment to 1 month after treatment
Range of center of pressure (COP) sway
Center of pressure (COP) sway range of subjects on stable and unstable surfaces is measured via a balance board during two standing conditions: single-task quiet standing and dual-task standing. The dual-task standing requires subjects to continuously perform serial subtraction of 7 from random numbers ranging from 400 to 600 while maintaining standing posture. The balance board records the maximum displacement range of COP deviation under both single-task and dual-task standing states. This indicator objectively assesses postural stability and balance regulation ability on different surfaces; abnormal increases indicate deteriorated postural control, aiding evaluation of balance disorder severity and intervention effectiveness.
Time frame: From the enrollment to 1 month after treatment
Path of center of pressure (COP) sway
Center of pressure (COP) sway path of subjects on stable and unstable surfaces is measured via a balance board during two standing conditions: single-task quiet standing and dual-task standing. The dual-task standing requires subjects to continuously perform serial subtraction of 7 from random numbers ranging from 400 to 600 while maintaining standing posture. The balance board records the total traveling path length of COP movement under both single-task and dual-task standing states. This indicator objectively reflects the complexity and stability of postural adjustment during standing on different surfaces; abnormal increases indicate inefficient balance control and postural instability, aiding evaluation of balance disorder severity and intervention effectiveness.
Time frame: From the enrollment to 1 month after treatment
Area of center of pressure (COP) sway
Center of pressure (COP) sway area of subjects on stable and unstable surfaces is measured via a balance board during two standing conditions: single-task quiet standing and dual-task standing. The dual-task standing requires subjects to continuously perform serial subtraction of 7 from random numbers ranging from 400 to 600 while maintaining standing posture. The balance board records the planar enclosed area covered by continuous COP movement under both single-task and dual-task standing states. This indicator objectively evaluates the overall stability of standing posture and anti-interference ability on different surfaces; abnormal increases represent expanded postural sway range and impaired balance function, aiding evaluation of balance disorder severity and intervention effectiveness.
Time frame: From the enrollment to 1 month after treatment
Diffusion Tensor Imaging(DTI)
Functional MRI is used to acquire Diffusion Tensor Imaging(DTI) data. DTI characterizes white matter microstructural integrity and fiber tract organization. This measure evaluates brain function and structural connectivity associated with motor and cognitive performance.
Time frame: From the enrollment to 1 month after treatment
Timed Up and Go (TUG) Test Time
The time consumed by subjects to complete the standard Timed Up and Go (TUG) test is recorded as the evaluation outcome. During the test, subjects are required to finish a series of standardized movements including standing up from a chair, straight walking, turning around, and sitting back down independently. This indicator objectively assesses basic walking ability, functional mobility and gross motor control ability of subjects; prolonged completion time indicates impaired walking and mobility function, aiding the evaluation of motor dysfunction severity and intervention effectiveness.
Time frame: From the enrollment to 1 month after treatment
Dual-Task Timed Up and Go (Dual-Task TUG) Test Time
The time consumed by subjects to complete the dual-task Timed Up and Go (TUG) test is recorded as the evaluation outcome. During the dual-task test, subjects are required to finish the entire standard TUG motor sequence while simultaneously performing continuous serial subtraction of 7 from random numbers within 100, which imposes additional cognitive load during walking. This indicator comprehensively reflects subjects' dual-task execution ability, integrating walking mobility and cognitive-motor coordination capacity. Increased completion time represents declined dual-task processing efficiency and compromised gait stability under cognitive interference, aiding the evaluation of comprehensive motor-cognitive function and intervention effectiveness.
Time frame: From the enrollment to 1 month after treatment
The score of the Parkinson's Disease Questionnaire-39 (PDQ-39)
The PDQ-39 is a standardized patient-reported outcome tool to evaluate the health-related quality of life in people with Parkinson's disease. It consists of 39 items covering 8 dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort), with a scoring range of 0 to 100 points, where higher scores indicate a poorer quality of life.
Time frame: From enrollment to 1 month after treatment
The score of the Pittsburgh Sleep Quality Index (PSQI)
The PSQI is a standardized assessment tool to evaluate sleep quality and sleep disturbances in people with Parkinson's disease. It has a scoring range of 0 to 21 points, with higher scores indicating more severe sleep disorders.
Time frame: From enrollment to 1 month after treatment
Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 5 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ke Dong, MD